Health
Mak Grants Professors David Serwadda, Phillipa Musoke a Lifetime Professor Emeritus Appointment
Professor David Serwadda has been offered a lifetime professor emeritus position at Makerere University. This decision was reached at the 489th meeting of Makerere University Council, the supreme governing body of the university, on recommendation and nomination of the chief academic organ of the University, the Senate acknowledging his exceptional contributions to academia.
The prestigious title of Emeritus Professor, is bestowed upon retired professors in line with the university’s policies, aims to retain exemplary scholars who have reached the mandatory retirement age. This is in accordance with the University’s Policy and Procedures for The Award of The Title “Emeritus Professor”; The purpose is to retain an academician who has attained his or her mandatory retirement age under the existing Employment Policy of the University.
Pursuant to university policy, an Emeritus Professor is expected to embody a set of key responsibilities, such as mentoring, continuous knowledge generation in his or her field of specialization, and promoting research and publications in peer-reviewed journals.
Professor Serwadda, 67, is an icon of academic excellence, prolific researcher and an expert in infectious disease-focused public health deeply interested in HIV clinical drug trials, HIV epidemiology, infectious disease surveillance, and HIV intervention program assessment. His great contributions have had a significant impact on the academic landscape over the course of a distinguished professional history that extend over 35 years having been appointed in Makerere University in 1993 and gone through the ranks to full Professor. This has been demonstrated in his research endeavors at Makerere University, leadership roles, and comprehensive teaching across undergraduate, master’s, and PhD levels.
In 1982, Professor Serwadda received his medical degree from Makerere University after which he went to Newcastle Upton Tyne Medical School in England for a Master of Science in Medicine in 1987. In 1990, he completed his Master of Medicine in Internal Medicine Makerere University in 1990 and subsequently obtained a Master of Public Health (Epidemiology) from the John Hopkins School of Hygiene in the United States in 1991. In recognition of his outstanding leadership in the HIV/AIDS response and his noteworthy scientific accomplishments, John Hopkins University awarded him an honorary doctorate in 2011.
In his illustrious university service career, that started off in the Department of Disease Control and Environmental Health at Makerere University School of Public Health (MakSPH), then Institute of Public Health (IPH). He was director and eventually Dean of the School of Public health for 8 years. Professor Serwadda is commended for his meritorious service to Makerere University he has excelled in teaching, mentorship of students and junior staff made significant contribution to both national and international research. Notable for his resourcefulness, extensive networks, and scholarly integrity, Prof. Serwadda’s vast contributions significantly elevated infectious disease research, boasting an impressive repertoire of approximately 400 publications.
He was instrumental in the founding of the Rakai Health Sciences Program, Makerere Walter Reed Project, and the Infectious Disease Institute (IDI) enhancing prominence both domestically and globally by means of innovative research endeavors.
Moreover, Prof. Serwadda’s remarkable memberships in eminent professional associations, broad committee participation, and recent appointment as Senior Editor of the acclaimed eLife Journal highlight his worldwide influence and dedication to the promotion of public health.
He is a reviewer of research proposals for; the National Institute of Health, Non-communicable illness in low-middle income countries 2016-; and Wellcome trust, population and public health 2008- and has attracted the University numerous research funds. Currently, he is the chair of the fundraising committee for MakSPH infrastructure, where he initiated the conversation with Johns Hopkins University and worked with the dean to negotiate a partnership that led to in the 1.1 million USD construction grant from Johns Hopkins University for American Schools and Hospitals Abroad (ASHA).
Professor Serwadda has demonstrated outstanding leadership in community service while serving in important roles at Makerere University, including Dean of the School of Public Health (2007–2009) and Director of the Institute of Public Health (2002–2007). Prior, he headed the Department of Environmental Health and Disease Control from 1999 to 2002 and served as the Executive Director of the Rakai Health Sciences Program from 1998 to 2017. He championed the creation of the MakSPH Grants Committee and Office, which he served as its chair until 2021. He currently serves on the Grants Management Committee of the Makerere University Research and Innovations Fund (MakRIF).
Several awards and honors have been bestowed upon Professor Serwadda. These include the following: The Visionary Guidance award by Uganda Health Marketing Group (2016); the Outstanding dedication to the HIV and AID response through services to TASO award in 2015; the Makerere University College of Health Sciences, School of Public Health founder; and the visionary and exceptional leadership in nurturing the HIV fellowship PROGRAM – 2014. Award of appreciation given in honor of the exceptional volume of scientific publications in 2013 Distinguished Service Award, British Council, 2008; Pioneer in Behavior-Based HIV Prevention, Harvard University, December 2006; Honorary Doctorate, John Hopkins University, May 2011; Johns Hopkins Bloomberg School of Public Health Alumni Knowledge of the World Award, October 2010.
The Vice Chancellor Professor Barnabas Nawangwe described the duo as long-serving and dedicated academics, who have diligently served Makerere University and Uganda at the College of Health Sciences until retirement.
“By accepting the appointment of Professor Emeritus, both Prof. Philippa Musoke and Prof. David Serwadda have expressed their readiness to allow Makerere University to continue tapping into their expertise and wealth of experience to mentor the next generation of academics and researchers, and to continuously generate knowledge in their fields of specialization, and promote research, publications and innovation. I thank them for their selfless service and congratulate them on this achievement,” said Professor Nawangwe.
Professor Philippa Musoke (MBChB, FAAP, PhD) is a US board-certified Paediatric Infectious Diseases specialist in the Department of Paediatrics and Child Health, School of Medicine College of Health Sciences, Makerere University and is currently based at the Makerere University-Johns Hopkins University Research Collaboration in Kampala Uganda. Prof. Musoke chairs the Ministry of Health PMTCT and the paediatric antiretroviral treatment technical subcommittees.
Prof. Musoke has dedicated the past 28 years to teaching at the Makerere Medical School, treating sick children at the Mulago National Referral Hospital, and conducting research at MU-JHU Care Ltd. She has supervised and mentored numerous medical students, postgraduate students including PhD candidates, and junior faculty. At MUJHU, she has mentored and inspired multiple junior investigators, enabling them to become independent investigators. Prof. Musoke is dedicated and committed to excellence in clinical care, training and research.
She is currently the international vice chair of the US, National Institutes of Health (NIH), Division of AIDS, IMPAACT network. Prof. Musoke has published over 150 articles in peer-reviewed journals, presented research findings at national and international conferences, and contributed to the prevention and management of HIV globally. Prof. Musoke is a technical advisor for WHO and other international health organizations.
Since 1995, she has conducted multiple perinatal HIV prevention clinical trials addressing important challenges like the benefit of single dose nevirapine (NVP) to the mother at the onset of labor and her infant at birth to reduce mother-to-child HIV transmission (MTCT) (HIVNET012), infant nevirapine dosing for prevention of breast milk HIV transmission (HPTN046), and the benefit of triple antiretroviral therapy during pregnancy and breastfeeding in further reducing MTCT (PROMISE).
Makerere University’s School of Public Health (MakSPH) showcased research, training and international partnerships supported through European Union funding during the EU Uganda Research and Study Fair 2026 held at Makerere University.
The fair brought together students, researchers, academics, government representatives and development partners to explore opportunities in education, research, innovation and international collaboration, while celebrating 50 years of partnership between Uganda and the European Union.
Through its exhibition, MakSPH highlighted research and capacity building initiatives addressing public health challenges including infectious diseases, non communicable diseases, health systems, climate change and pandemic preparedness.
18 EU funded projects supported at MakSPH
Prof. Rhoda Wanyenze, Dean of Students, School of Public Health, said the School has benefited from 18 EU funded projects over the past five years, supporting research and training across several areas of public health.
She said the projects have contributed to the training of PhD researchers and the development of research addressing infectious diseases and prevention, non communicable diseases, health systems, climate change and health.
Prof. Wanyenze also highlighted a new five year programme which started in 2021 that is aiming at strengthening capacity for research on pandemic preparedness and response, including outbreaks such as Ebola.
Another programme being undertaken with the Ministry of Health and Karolinska Institute focuses on improving maternal health while also addressing adolescent pregnancy and the health of mothers and children.
She described partnerships as critical to advancing science and innovation, noting that collaboration allows researchers in Africa and Europe to share knowledge and strengthen the impact of research on communities.
Research partnerships strengthen innovation
Prof. Robert Wamala, Director of the Directorate of Research, Innovation and Partnerships at Makerere University, said the exhibition provided an opportunity to showcase EU funded projects across the University.
He noted that the School of Public Health alone has more than 18 such projects, while other colleges also have several EU supported initiatives.
One of the projects showcased was PREPARE TID, a partnership aimed at developing rapid diagnostic technologies for emerging and re emerging infectious diseases.
Prof. Julius Okuni, Associate Professor of Veterinary Pathobiology and Molecular Diagnostics at Makerere University, said the project brings together universities, industries and other organisations from Africa and Europe.
The project is working to develop technologies that can quickly identify pathogens responsible for outbreaks such as Ebola, Rift Valley fever and Crimean Congo haemorrhagic fever.
According to Prof. Okuni, Makerere is involved in field and laboratory work to test and refine the technologies before they can be delivered to end users.
Fair provides platform for research visibility
For researchers at MakSPH, the fair also provided an opportunity to increase the visibility of ongoing research and create new connections with researchers, policymakers and potential funders.
Dr. Raymond Tweheyo, Honorary Lecturer and Senior Research Fellow in the Department of Health Policy, Planning and Management, said such exhibitions allow researchers to share their work and identify others working on related challenges.
He cited the CONNECT for Health project, which focuses on transforming non-communicable disease care in Uganda through collaboration with partners across several countries.
Dr. Tweheyo said exhibitions can help researchers connect with policymakers, civil society organisations and other partners who can contribute to translating research into practical solutions.
Assoc. Prof. Angelina Kakooza Mwesigye, Associate Professor and Child Neurologist at Makerere University College of Health Sciences, also emphasised the importance of exposing young people to international research opportunities.
She said the long standing Uganda Europe partnership provides opportunities for the next generation of researchers to learn, build networks and prepare for future research collaborations.
The School of Public Health’s participation highlighted the role of international partnerships in strengthening research capacity, supporting innovation and developing evidence based responses to Uganda’s public health challenges.
Uganda has strengthened its ability to respond rapidly to Ebola and Marburg outbreaks once cases are confirmed, but delays in frontline detection, health worker exposure, emergency financing bottlenecks and incomplete implementation of lessons from previous outbreaks continue to undermine preparedness, a study has found.
The findings were presented today, October 6, 2026, during a country validation workshop convened by the Meeting Targets and Maintaining Epidemic Control (EPiC) project, to examine lessons from Uganda’s response to filovirus disease outbreaks. The study was undertaken by Makerere University School of Public Health and FHI 360.
Presented by Dr. Steven Kabwama, the synthesis examined Uganda’s experience with recurrent Ebola virus disease (EVD) and Marburg virus disease (MVD) outbreaks between 2000 and 2026, drawing particularly on After-Action Reviews from the 2017 Marburg outbreak and the 2019, 2022 and 2025 Ebola outbreaks. The work seeks to consolidate recurring strengths, weaknesses, innovations and lessons that had previously been documented separately.
Uganda has recorded 12 filovirus outbreaks over the 26-year period, including nine Ebola and three Marburg outbreaks, according to the research team. Among the four outbreaks examined closely were the 2017 Marburg outbreak in Kween and Kapchorwa, the cross-border Ebola outbreak in Kasese in 2019, the multi-district Sudan Ebola virus outbreak in 2022, and the 2025 outbreak whose index case was a health worker.
Strong systems after confirmation
Across the outbreaks reviewed, the synthesis found that Uganda has developed significant capacity to mobilise after laboratory confirmation. National and district task forces and technical response structures are activated quickly, supported by strong laboratory capacity, established coordination mechanisms and increasingly sophisticated surveillance systems.
The country has also built laboratory capacity around the Uganda Virus Research Institute, mobile laboratories, genomic sequencing, sample referral systems and the Results Dispatch System. Digital surveillance tools, Village Health Teams, survivor champions and established national and district coordination structures have further strengthened response capacity.
Detection remains a weak point
However, the findings point to a critical problem before confirmation: recognising a possible outbreak early enough.
For outbreaks originating within Uganda, the synthesis found that the period between a patient’s first presentation and confirmation ranged from nine to 27 days. This the study found is linked to low clinical suspicion and weaknesses in screening. Other recurring challenges included delayed access to emergency financing, infections among health workers, disruptions to essential health services, community mistrust and stigma, and limited follow-through on recommendations from previous After-Action Reviews.
Opening the workshop, the Dean, Prof. Rhoda Wanyenze, said understanding these delays requires going beyond identifying broad weaknesses to examining where response systems fail in practice.
“We can identify a broad challenge such as delayed detection from the literature, but your experience on the ground can help us understand the specific factors that create that challenge,” Prof. Wanyenze said while addressing district health officials from across the country.
“When we begin looking for solutions, we need to be able to target the actual problems rather than simply identifying broad challenges.”
The workshop brought together partners and colleagues from districts, including people directly involved in outbreak response, to validate the synthesis against frontline experience. Prof. Wanyenze noted that published literature, scientific papers and response reports cannot capture every operational reality, making practitioner experience essential to understanding where delays occur and what interventions have worked. Remarks validation workshop
Turning outbreak experience into continuous readiness
Among the priority actions proposed are stronger screening and alert systems for earlier detection; ring-fenced emergency financing and more reliable responder payment systems; routine infection prevention and control training; stronger occupational protection for health workers; continued investment in laboratories and genomic sequencing; and preparedness extending beyond districts traditionally considered outbreak hotspots. The study also recommends stronger community engagement and a formal mechanism to track and finance implementation of recommendations from After-Action Reviews.
Dr. Andrew Acero, Director of the EPiC project at FHI 360’s Uganda Office said the central challenge is ensuring that experience accumulated during successive outbreaks translates into lasting institutional capacity.
“The real value lies in ensuring that what we learn changes what we do. Our findings should inform policy, shape guidelines and training, strengthen systems and ultimately improve practice.”
He noted that preparedness cannot begin only after an emergency has been declared, but must be built through sustained relationships, systems and capacity before outbreaks occur. Remarks validation workshop
The EPiC project is led by FHI 360 with core partners including Right to Care, Palladium and Population Services International.
Uganda’s latest national HIV survey reveals lower viral suppression among adolescents and young adults living with HIV than among older adults, even as the country records substantial improvements in controlling the virus. The findings come from Uganda Population-Based HIV Impact Assessment (UPHIA 2025), a national household survey examining HIV prevalence and whether people living with the virus know their status, receive treatment, and achieve viral suppression.
Releasing the preliminary UPHIA 2025 findings at the Uganda Media Centre on 1 October 2026, Minister of Health Hon. Dr. Chris Baryomunsi called for earlier prevention and testing, particularly among adolescent girls and young women, alongside support for treatment adherence. “We must reach out to the young people, ensure that they have information, they test, take treatment, and adhere to the treatment guidance,” he urged.
Hon. Baryomunsi recalled how fear had discouraged testing during his university years: “I remember when we were at university, we went for testing at the university hospital. We sat there for three hours. Some of us left without even testing because it was scary.” Today, he explained, “even if you test HIV positive, you can be initiated on treatment, and you live normally like the rest of those who don’t have HIV.”
UPHIA 2025 was locally led under the Ministry of Health’s overall leadership, with Makerere University School of Public Health serving as the prime implementer, a role ICAP at Columbia University held in the previous two surveys. The Uganda Bureau of Statistics led sampling, while the Uganda Virus Research Institute and National Health Laboratory and Diagnostic Services led laboratory operations. Regional referral hospitals and local governments supported implementation, and the U.S. government provided US$10 million through PEPFAR, along with technical assistance from the U.S. CDC.
UPHIA collected data from July to September 2025 among people aged 15 and above, including those outside routine treatment services. Of 6,283 eligible households, 94.4% completed interviews. Researchers interviewed 13,801 people and tested 13,477 for HIV.
Testing followed Uganda’s national algorithm, with laboratory confirmation of positive samples, viral-load measurement, and checks for antiretroviral medicines to establish treatment use. Researchers weighted the estimates to account for the sampling design. Participants received counselling and results, and those who tested positive were referred for treatment.
Hon. Baryomunsi thanked participants and their families for welcoming survey staff and contributing their time, information and samples, without which the national evidence would not have been available.
National progress and the youth gap
The survey estimated HIV prevalence, which means the proportion of people living with HIV, at 5.9% among those aged 15 and above, corresponding to about 1.496 million people in this age group nationwide. Prevalence was 7.3% among women and 4.1% among men, ranging from 1.3% in Karamoja to 8% in the South Western region.
Among people aged 15 and above living with HIV, 86% had achieved viral suppression, meaning a low amount of HIV in the blood, measured in UPHIA as fewer than 1,000 copies per millilitre. Suppression stood at 69.3% among adolescents and young adults aged 15–24 living with HIV, compared with 89.9% among those aged 50 and above. These estimates cover people living with HIV regardless of whether they know their status or receive treatment.
HIV prevalence among people aged 15–24 was 1.5%, including 2% among young women and 1% among young men. Among young women, prevalence was 1.3% at ages 15–19 and 2.8% at ages 20–24. These differences support attention to earlier prevention and testing, although they do not establish when infections occurred.
The highest prevalence estimates occurred among middle-aged adults: 15.7% among women aged 40–44 and 11.7% among men aged 45–49. Lower suppression among young people therefore requires attention alongside the higher HIV prevalence among middle-aged adults. Comparing the same age group across both surveys, viral suppression among people aged 15–64 increased from 74.9% in 2020–21 to 86.1% in 2025, while HIV prevalence remained at 5.9%.
Diagnosis and the path to 2030
The treatment results identify diagnosis as the main national gap. Among people aged 15 and above living with HIV, 85.3% knew their status. Of those aware, 99.1% were receiving treatment; among those receiving treatment, 96.5% had achieved suppression.
The 95-95-95 targets aimed for 95% of people living with HIV to know their status, 95% of those diagnosed to receive treatment, and 95% of those receiving treatment to achieve viral suppression by 2025. Among people aged 15 and above, Uganda exceeded the treatment and suppression targets, while diagnosis remained below target. UNAIDS’s Global AIDS Strategy 2026–2031 retains these targets towards ending AIDS as a public health threat by 2030.
According to WHO, viral suppression protects health and helps prevent HIV transmission. Uncontrolled HIV weakens the immune system, increasing the risk of serious illness. With continued treatment as prescribed, sexual transmission risk is negligible when HIV remains suppressed but detectable, and zero when undetectable. The Uganda AIDS Commission estimated over 34,000 new HIV infections in 2025, underscoring the importance of early diagnosis, timely treatment, and sustained suppression alongside other prevention measures.
The demographic stakes are substantial. People aged 15–24 constituted 21.2% of Uganda’s population in the 2024 census. The country’s Fourth National Development Plan, covering 2025–2030, prioritises a healthy, knowledgeable, skilled and productive population and reducing HIV through primary health care. Protecting young people’s health, therefore, supports their participation in education, work, and national development; UPHIA helps identify where services need greater attention.
Turning evidence into action
The study’s conclusions identify three priorities: sustain treatment outcomes, find people unaware of their status, and improve suppression among younger people. Permanent Secretary Dr. Diana Atwine connected the findings to the Ministry’s planning.
“We do believe that these results are a true reflection of what is happening in our country as far as the HIV status is concerned, and we do believe that it will give us a very clear direction and the roadmap that we are going to take in the next five years to target and to get our targets achieved.”
Acting on these priorities requires funding for services and research. Hon. Baryomunsi outlined plans to target resources where needs are greatest, strengthen district services and align partner support with government priorities. Responding to journalists’ questions, he noted the government’s intention to increase domestic funding for the HIV response, including research.
“The HIV/AIDS response, including research and surveys such as this one, has largely been funded by partners in the past. The government of Uganda is committed to allocating more resources from our domestic budget to support the response and research,” he noted.
For the first time in the UPHIA series, the survey assessed selected noncommunicable disease indicators among people aged 15 and above: 15.5% had elevated blood pressure, 24.8% were overweight or obese, and 0.9% had raised random blood glucose. These screening findings align with the Ministry’s integration agenda and Hon. Baryomunsi’s call to bring HIV and chronic care services together to address people’s wider health needs.
Speaking at the release of the preliminary results, U.S. Embassy Chargé d’Affaires Mikael (Mika) Cleverley described UPHIA 2025 as the first Population-Based HIV Impact Assessment worldwide fully led and implemented by the country itself.
“The study was led by Ugandan scientists, Ugandan managers, Ugandan public servants, Ugandan field teams, from design to data collection to analysis. And this is what two decades of focused strategic U.S. foreign investments in the public health sector was meant to produce, is to reinforce Ugandan leadership and Ugandan-led efforts.”
At the survey launch on 29 May 2025, MakSPH Dean Prof. Rhoda Wanyenze highlighted the partnership’s contribution: “The partnership between Makerere University and CDC has not only helped build national capacity in surveillance and epidemiology, but has also strengthened our ability to lead high-quality, large-scale national surveys.”
The Dean added: “After two decades of joint work, we are proud that UPHIA is now a fully Ugandan-led effort. This is critical to the sustainability of the skills and knowledge generation to inform our local response.”
UPHIA 2025 shows how far Uganda’s HIV response has advanced and where gaps remain. As the country works towards ending AIDS as a public health threat by 2030, reaching young people with testing, treatment, and continued care will be essential to extending those gains.
Read the full UPHIA 2025 summary results here:
-
General1 week agoStatement on Concerns Circulating Regarding a Member of Academic Staff
-
General1 week agoPress Statement: Incident Involving Death of a Student at Makerere University
-
General2 weeks agoMakerere Marathon 2026 – Running to Equip the Disability Support Center
-
General1 week agoBeyond Map Size: Africa’s Agency Should Not Be Funded by Other People
-
General2 weeks agoJNLC Leadership Symposium Equips Young Leaders for Responsible and Transformative Leadership